Financial Performance - The profit for H1 2025 amounts to DKK -9.5 million, an improvement from DKK -12.9 million in H1 2024 [4] - Total assets as of 30 June 2025 are DKK 62.3 million, slightly down from DKK 63.2 million in the previous year [2] - Equity has significantly increased to DKK 39.4 million as of 30 June 2025, compared to DKK 12.4 million a year earlier [4] Cash Position - Cash and cash equivalents as of 30 June 2025 are DKK 0.7 million, down from DKK 0.9 million in H1 2024 [4] - Convertible loans decreased to DKK 15.2 million from DKK 18.5 million year-over-year [2] Strategic Developments - The company has launched a new strategy aimed at driving growth and enhancing shareholder returns [3] - Clinical trial applications for RNX-011 (peritonitis) and RNX-051 (Colorectal Adenoma and Colon Cancer) have been submitted to Danish authorities in H1 2025 [3] - The company continues discussions with potential licensing partners to further its strategic goals [3] Leadership Changes - Christian Henrik Tange was appointed as the new CEO of Pharma Equity Group on 1 April 2025 [3] - Sebastian Bo Jakobsen was appointed as CEO of the subsidiary Reponex Pharmaceuticals A/S [3] Company Overview - Pharma Equity Group A/S is a life sciences investment and development firm listed on the Nasdaq Copenhagen stock exchange, focusing on pharmaceuticals, medical technology, and medical devices [5] - The company aims to identify and advance innovations, particularly from Scandinavian research institutions, to create impactful healthcare solutions [5]